.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FD06_Margetuximab.Margetuximab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FD06_Margetuximab.Margetuximab| name: | Margetuximab | |
| ATC code: | L01FD06 | |
| route: | intravenous | |
| compartments: | 2 | |
| dosage: | 1500 | mg |
| volume of distribution: | 3.29 | L |
| clearance: | 0.2 | L/h |
| other parameters in model implementation | ||
Margetuximab is a chimeric, Fc-engineered, humanized IgG1 monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2). It is used in the treatment of HER2-positive metastatic breast cancer, typically in combination with chemotherapy, and is approved for use in adult patients who have received two or more prior anti-HER2 regimens.
Population pharmacokinetics in adult patients with advanced HER2-positive breast cancer; both sexes included. Parameter values are derived from published PK analyses in patients receiving recommended dose regimen.